Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics

Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics

The objectives of this study are: 1) to design new diagnostic criteria used to accurately define heart failure with preserved ejection fraction (HFpEF); 2) to better define the risk factors associated with HFpEF; 3) to elucidate the clinical, cellular and molecular mechanisms involved with the development and progression of HFpEF; 4) to design and test new therapeutic strategies for patients with HFpEF.

Inclusion Criteria:

• Group 1 No clinically overt heart failure
• Group 2 Known coronary artery disease
• Group 3 Known heart failure with preserved ejection fraction
• Group 4 Known heart failure with reduced ejection fraction
• Group 5 Healthy age-matched controls

Exclusion Criteria:

• Age <18 years
• Known malignancy with expected survival <1 year
• Pregnant or recent pregnancy <6 months
• Recent event (<2 weeks since Acute Coronary Syndrome, Heart failure or other admission
• Severe mitral or aortic stenosis